Literature DB >> 16426723

Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows.

M J Appel1, H A van Veen, H Vietsch, M Salaheddine, J H Nuijens, B Ziere, F de Loos.   

Abstract

The oral toxicity of recombinant human lactoferrin (rhLF) produced in the milk of transgenic cows was investigated in Wistar rats by daily administration via oral gavage for 13 consecutive weeks, 7 days per week. The study used four groups of 20 rats/sex/dose. The control group received physiological saline and the three test groups received daily doses of 200, 600 and 2000 mg of rhLF per kg body weight. Clinical observations, growth, food consumption, food conversion efficiency, water consumption, neurobehavioural testing, ophthalmoscopy, haematology, clinical chemistry, renal concentration test, urinalysis, organ weights and gross examination at necropsy and microscopic examination of various organs and tissues were used as criteria for detecting the effects of treatment. Overall, no treatment-related, toxicologically significant changes were observed. The few findings that may be related to the treatment (lower cholesterol in high-dose females, lower urinary pH in high-dose males and females and very slightly higher kidney weight in high-dose females) were considered of no toxicological significance. Based on the absence of treatment-related, toxicologically relevant changes, the no-observed-adverse-effect level (NOAEL) was considered to be at least 2000 mg/kg body weight/day.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426723     DOI: 10.1016/j.fct.2005.11.012

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  2 in total

1.  Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Biochimie       Date:  2008-04-27       Impact factor: 4.079

2.  Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2019-01-08       Impact factor: 79.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.